1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Vaccines: The End of Illness Overview

Vaccines: The End of Illness Overview

  • November 2014
  • -
  • Insight Pharma Reports
  • -
  • 164 pages

New to Insight Pharma Reports is Vaccines: The End of Illness. This report focuses on the most recent vaccine research, emphasizing their reputation as an unmatched tool of efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing a fundamental revolution, taking advantage of the profound understanding of the immune system and its ability to mount protective antibody production and cell-based responses to foreign antigens. Understanding these properties will not only enable the development of innovative diagnostics but also the advancement of therapeutic applications.

Specific Highlights Include:

This report profiles some of the major pharma companies involved in vaccine R&D and a number of biotech companies developing new vaccine products and technologies – including 35 small pharma companies and 8 big pharma companies profiled
The logistics and management of the vaccine industry are increasingly based on partnerships between the private sector (pharma and biotech companies), government agencies (WHO) and large non-profits (such as the Gates Foundation).
An assessment of the future directions of vaccines as innovative medical therapies for a wide range of diseases.
Explores conditions not normally thought to be in purview of vaccination, including substance abuse and neurological disorders such as Alzheimer’s disease and Parkinson’s disease.
Survey of industry experts concerning the political economic and technological future of vaccine technology.
Over 20 pages of pipeline and clinical trial data specific to vaccine targets
Over 30 pages of pipeline and clinical trial data specific to cancer vaccines

Table Of Contents

Vaccines: The End of Illness Overview
Executive Summary
Chapter 1: Introduction
1.1 The History of Vaccination
1.1.1 Ancient
1.1.2. 18th century
1.1.3. 19th century
1.1.3.1. Pasteur
1.1.3.2. Coley's toxins
1.1.4. Mid 20th century
1.2. Vaccines in the Doldrums: late 20th century
1.2.1. Liability issues
1.2.2. Vaccine denialism
1.3. The Current State of Vaccine technology, 2013
1.3.1. WHO
1.3.2. Behemoth players: Bill and Melinda Gates
1.3.3. Big pharma jumps in

Chapter 2: A Cornucopia of Vaccine Technologies
2.1. Vaccine production: eggs versus cell culture
2.2. Cell line options
2.3 Conventional Vaccines
2.4. Adjuvants
2.5. Nanoparticle-based vaccines
2.6. DNA Vaccines
2.7. Vaccines driving T-cell activation
2.8. Dendritic cells

Chapter 3: Vaccine Targets
3.1. Infectious Diseases
3.1.1. Influenza
3.1.2. HSV A and B
3.1.3. C. difficile
3.1.4. HIV
3.1.5. Pneumococcus
3.1.6. Typhoid
3.1.7. Candida
3.1.8. Rabies
3.1.9. Rotavirus
3.1.10. Polio
3.1.11. Malaria
3.1.12. Parasitic diseases
3.1.13. Smallpox
3.1.14. Cholera
3.1.15. Mumps
3.1.16. Diphtheria
3.2. Cancer vaccines
3.2.1. Human papilloma virus
3.2.2. Breast cancer
3.2.3. Pancreatic cancer
3.2.4. Renal cell carcinoma
3.2.5. Melanoma: dendritic cells
3.2.6. Prostate cancer

Chapter 4: Big Pharma Vaccines
4.1. AstraZeneca (Medimmune)
4.2. Baxter
4.3. GSK
4.4. JandJ (Crucel)
4.5. Merck
4.6. Novartis
4.7. Pfizer
4.8. Sanofi

Chapter 5: Small Pharma Vaccines
5.1. AC Immune
5.2. Aeras
5.3. Alphavax
5.4. Astrellas
5.6. Bavarian Nordic
5.7. BiondVax Pharmaceuticals
5.8. Braasch Biotech LLC
5.9. Celldex
5.10. Chrontech
5.11. Emergent Biosolutions
5.12. EpiVax
5.13. GenVec
5.14. GeoVax
5.15. Genocea Biosciences
5.16. Immune Targeting Systems
5.17. Indian Immunologicals Limited
5.18. Inovio
5.19. Inviragen
5.20. Juvaris Biotherapeutics
5.21. Medicago
5.22. Mymetics
5.23. NovaRx
5.24. Novavax
5.25. Nuron
5.26. OPKO
5.27. Profectus Bioscience Inc
5.28. Sinovac
5.29. Sorrento Therapeutics, Inc.
5.30. TapImmune
5.31. Valneva
5.32. VaxInnate
5.33. VaxLiant
5.34. VBI vaccines
5.35. Vical

Chapter 6: Regulatory Issues
6.1. A bumpy road
6.2. Current regulatory status

Chapter 7:The Future of Vaccine technology
7.1. Challenges in delivery and storage
7.2. Dry vaccine technology: Ready for prime time?
7.3. A universal Vaccine
7.4. Outlandish targets
7.4.1. Drug abuse
7.4.2. Obesity
7.4.3. Smoking
7.4.4. Alcoholism
7.4.5. Alzheimer's disease
7.4.6. Parkinson's Disease
7.5. Bioterrorism: A global threat?
7.6. Intellectual Property in the Balance
7.7. A bright future for Vaccines

Chapter 8: Survey of Opinion Concerning Vaccine technology by Members of the Industry

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2017 World Transfusion Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Transfusion Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 43500
  • Industry report
  • January 2017
  • by Venture Planning Group

This comprehensive 68-country report from VPGMarketResearch.com provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market ...

2017 World Blood Typing, Grouping and Infectious Disease Screening Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Blood Typing, Grouping and Infectious Disease Screening Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 43500
  • Industry report
  • January 2017
  • by Venture Planning Group

This comprehensive 68-country report from VPGMarketResearch.com provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market ...


Download Unlimited Documents from Trusted Public Sources

Diabetes Statistics - Forecast

  • March 2017
    5 pages
  • Diabetes  

View report >

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Diabetes Statistics in Bangladesh and Germany

  • March 2017
  • Diabetes  

    Cardiovascular ...  

    Type 2 Diabetes  

  • Bangladesh  

    Germany  

View report >

Diabetes Statistics

26 hours ago

Diabetes Statistics

26 hours ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.